0001610717-24-000027.txt : 20240111
0001610717-24-000027.hdr.sgml : 20240111
20240111195941
ACCESSION NUMBER: 0001610717-24-000027
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240109
FILED AS OF DATE: 20240111
DATE AS OF CHANGE: 20240111
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Krause Kevin Michael
CENTRAL INDEX KEY: 0001916925
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41331
FILM NUMBER: 24530361
MAIL ADDRESS:
STREET 1: 369 27TH STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94131
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AN2 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001880438
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 820606654
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1800 EL CAMINO REAL, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94027
BUSINESS PHONE: (650) 331-9090
MAIL ADDRESS:
STREET 1: 1800 EL CAMINO REAL, SUITE D
CITY: MENLO PARK
STATE: CA
ZIP: 94027
4
1
form4.xml
X0508
4
2024-01-09
0001880438
AN2 Therapeutics, Inc.
ANTX
0001916925
Krause Kevin Michael
C/O AN2 THERAPEUTICS, INC.
1800 EL CAMINO REAL, SUITE D
MENLO PARK
CA
94027
true
Chief Strategy Officer
true
Common Stock
2024-01-09
4
M
0
2417
0.42
A
4331
D
Common Stock
2024-01-09
4
M
0
5000
6.6
A
9331
D
Common Stock
2024-01-09
4
S
0
7417
20.1385
D
1914
D
Stock Option (right to buy)
0.42
2024-01-09
4
M
0
2417
0
D
2030-01-22
Common Stock
2417
49868
D
Stock Option (right to buy)
6.6
2024-01-09
4
M
0
5000
0
D
2031-04-29
Common Stock
5000
26832
D
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.
The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.
/s/ Lucy Day, Attorney-in-Fact for Kevin Michael Krause
2024-01-11